Q32 Bio Inc. (QTTB) Stock Forecast
QTTB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 7 analysts
- Price target
- $39.67 average of analyst targets
- Upside to target
- +427.5% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.36
- 52-week range
- $1.93 – $21.38
QTTB analyst ratings
7 analystsNumber of analysts at each rating.
QTTB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
QTTB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.33 | −$0.42 | −$0.27 | −$0.60 | +45.2% | 7 |
| Current fiscal year (2026) | −$1.50 | −$1.64 | −$1.37 | $2.42 | −162.0% | 7 |
| Next fiscal year (2027) | −$2.27 | −$3.14 | −$1.54 | −$1.50 | −51.1% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
QTTB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $333,330 | $0 | $2.0M | −99.4% | 6 |
| Next fiscal year (2027) | $833,330 | $0 | $5.0M | +150.0% | 6 |
QTTB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
QTTB revenue: reported and forecast
QTTB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.31 | −$0.33 | −$0.34 | −$0.33 | −14.0% | 2 up · 1 down |
| Current fiscal year (2026) | −$1.74 | −$1.50 | −$1.49 | −$1.52 | −$1.50 | −13.7% | 2 up · 1 down |
| Next fiscal year (2027) | −$1.97 | −$1.76 | −$1.82 | −$2.14 | −$2.27 | +15.0% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
QTTB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; QTTB beat in 9 of 12.
What analysts expect from QTTB
7 analysts cover Q32 Bio; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $39.67, 427.5% above the latest close of $7.52. Analysts expect earnings of −$1.50 per share for 2026, −162.0% from a year earlier. For 2027 the average estimate is −$2.27 per share on revenue of $0.8 million. Q32 Bio beat the EPS estimate in 9 of the last 12 quarters.
Related: QTTB income statement, QTTB key metrics, QTTB chart. See the QTTB stock overview for the latest quote and news.
QTTB forecast FAQ
What is Q32 Bio's price target?
The average analyst price target for Q32 Bio is $39.67, 427.5% above the latest close of $7.52.
Is Q32 Bio a buy, hold or sell?
Of 7 analysts covering Q32 Bio, 6 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Q32 Bio's EPS forecast?
Analysts forecast −$1.50 per share for 2026 (range −$1.64 to −$1.37); for 2027 the estimate is −$2.27.
What is Q32 Bio's revenue forecast?
The average revenue estimate for 2026 is $0.3 million, growth of −99.4%; for 2027 it is $0.8 million.
When does Q32 Bio report earnings?
Q32 Bio is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.36.
Does Q32 Bio usually beat earnings estimates?
Q32 Bio reported EPS at or above the analyst estimate in 9 of the last 12 quarters.